Skip to main content

Animations

MJFF Publications

6841 - 6850 of 8818 Results
Title
Year
  • Year
  • 2019
  • 2019
  • 2022
  • 2019
  • 2019
  • 2020
  • 2020
  • 2023
  • 2023
  • 2015
  • Summary Details
    OPEN
    Title: Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson’s disease.
    Journal Name: Neuropsychology
    Publisher: American Psychological Association (APA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1037/neu0000577
    Citation Count: 20
  • Summary Details
    OPEN
    Title: Depressive symptoms precede cognitive impairment in de novo Parkinson’s disease patients: Analysis of the PPMI cohort.
    Journal Name: Neuropsychology
    Publisher: American Psychological Association (APA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1037/neu0000583
    Citation Count: 32
  • Summary Details
    OPEN
    Title: Physical inactivity links depressive symptoms and cognitive functioning among individuals with Parkinson’s disease.
    Journal Name: Neuropsychology
    Publisher: American Psychological Association (APA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1037/neu0000837
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Sex Differences in Cognitive Changes in De Novo Parkinson’s Disease
    Journal Name: Journal of the International Neuropsychological Society
    Publisher: Cambridge University Press (CUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1017/s1355617719001085
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study
    Journal Name: The Lancet Digital Health
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s2589-7500(19)30105-0
    Citation Count: 103
  • Summary Details
    RESTRICTED
    Title: Developing therapies for Parkinson's disease
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30320-3
    Citation Count: 5
  • Summary Details
    RESTRICTED
    Title: Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30136-8
    Citation Count: 121
  • Summary Details
    RESTRICTED
    Title: α-synuclein seed amplification in Parkinson's disease – Authors' reply
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00371-x
    Citation Count: 5
  • Summary Details
    RESTRICTED
    Title: α-synuclein seed amplification in Parkinson‘s disease
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00373-3
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(15)00178-7
    Citation Count: 207
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.